This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on ISI (3)  • Contact me when this article is cited  Related Content  • Similar articles in this journal

Arch Intern Med. 2001;161:2263.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Ondansetron is a selective serotonin receptor (5-HT₃) antagonist that is widely used as an antiemetic agent for highly, and now increasingly for moderately, emetogenic chemotherapy.^1-2 Although this drug is very well tolerated, the US Food and Drug Administration has received 24 reports of adverse reactions associated with various clinical manifestations of anaphylaxis.³ Another report described 2 cases of anaphylactoid reactions associated with previous ondansetron exposure.⁴ We report a case of anaphylaxis in a patient with no prior ondansetron exposure.

Report of a Case

A 61-year-old woman with stage I_c ovarian cancer was to receive her first cycle of systemic adjuvant chemotherapy consisting of paclitaxel and cisplatin. Her history was significant for penicillin allergy, multiple prior exposures to corticosteroids, and long-term use of diphenhydramine hydrochloride for seasonal rhinitis.

Twelve hours before anticipated chemotherapy she premedicated herself with 800 mg of cimetidine hydrochloride and 20 mg of dexamethasone sodium phosphate, followed by another 20 mg . . . [Full Text of this Article]

Comment